<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01455441</url>
  </required_header>
  <id_info>
    <org_study_id>60 - TrainIncretin</org_study_id>
    <nct_id>NCT01455441</nct_id>
  </id_info>
  <brief_title>The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes</brief_title>
  <official_title>Does the GLP-1 Receptor Agonist (Victoza®) Improve the Metabolic Response to Physical Training in Patients With Type 2 Diabetes?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tina Vilsboll</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the effects of physical training in patients
      with type 2 diabetes during treatment with the GLP-1 receptor agonist liraglutide (Victoza®)
      in a 16-weeks double-blinded, randomized placebo-controlled clinical trial.

      Hypothesis: Physical training leads to better metabolic control in type 2 diabetic patients
      when training is combined with liraglutide (Victoza®) treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in HbA1c from baseline to 16 weeks. Glycated haemoglobin (HbA1c) is a form of haemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time (12 weeks).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal oxygen uptake (VO2peak)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Changes in VO2peak from baseline to 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>16 weeks</time_frame>
    <description>Changes in body weight from baseline to 16 weeks evaluated by a full body DEXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>16 weeks</time_frame>
    <description>Changes in blood pressure from baseline to 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycaemic control</measure>
    <time_frame>16 weeks</time_frame>
    <description>Changes in overall glycaemic control parameters, insulin sensitivity and beta cell function evaluated by The Homeostasis Model Assessment (HOMA) and incretin hormones response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meal test</measure>
    <time_frame>16 weeks</time_frame>
    <description>The changes in the postprandial response of incretin hormones, insulin and glucose, glucagon and the microvascular blood flow will be evaluated. Changes in blood leves of triglycerides and cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial echocardiography</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Training and liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with both training and liraglutide for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Training and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment wiht both training and placebo for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Training and liraglutide</intervention_name>
    <arm_group_label>Training and liraglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Training and placebo</intervention_name>
    <arm_group_label>Training and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed oral and written consent

          -  Diagnosed with type 2 diabetes according to the criteria of the WHO

          -  HbA1C: 7-11% (doing treatment with diet and/or metformin)

          -  Age &gt;18 years

          -  BMI &gt;25 kg/m2 &lt;40 kg/m2

          -  Negative islet cell antibodies (ICA) and glutamate decarboxylase 65 (GAD- 65)
             autoantibodies

        Exclusion Criteria:

          -  Females of child bearing potential who are pregnant, breast-feeding or have intention
             of becoming pregnant or are not using adequate contraceptive measures.

          -  Subjects treated with sulfonylureas, dipeptidyl peptidase 4 (DPP-4) inhibitors,
             insulin or glitazones

          -  Ongoing abuse of alcohol or narcotics

          -  Impaired hepatic function (liver transaminases &gt;2 times upper normal limit)

          -  Impaired renal function (se-creatinine &gt;150μM and/or albuminuria)

          -  Cardiac problems defined as decompensated heart failure (NYHA class III or IV),
             unstable angina pectoris and/or myocardial infarction within the last 12 months

          -  Uncontrolled hypertension (systolic blood pressure &gt;180 mmHg, diastolic blood pressure
             &gt;100 mmHg)

          -  Anaemia

          -  Any condition that the investigators feels would interfere with trial participation

          -  Receiving any investigational drug within the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Internal Medicine, Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2011</study_first_submitted>
  <study_first_submitted_qc>October 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>May 28, 2015</last_update_submitted>
  <last_update_submitted_qc>May 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Tina Vilsboll</investigator_full_name>
    <investigator_title>Professor dr.med</investigator_title>
  </responsible_party>
  <keyword>GLP-1</keyword>
  <keyword>Training</keyword>
  <keyword>Exercise</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

